Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Jesse Cedarbaum
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Living Beings
Concepts & Ideas
Procedures
Sign-in to see full Profile
Network (preview)
8
Stambler, Nancy
6
Lindsay, Ronald
4
Blass, John
4
Mitsumoto, Hiroshi
3
Lindsay, RM
3
Olanow, Warren
2
Quinlan, Edward
2
Gandy, Sam
2
Nguyen, Quan Dong
2
Campochiaro, Peter
2
Gjedde, Albert
2
Klinkosz, Bogdan
2
Shah, Syed Mahmood
2
Anand, Praveen
2
Sung, Jennifer
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Jesse Cedarbaum (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2006: Shah Syed Mahmood; Tatlipinar Sinan; Quinlan Edward; Sung Jennifer U; Tabandeh Homayoun; Nguyen Quan Dong; Fahmy Ahmed S; Zimmer-Galler Ingrid; Symons R C Andrew; Cedarbaum Jesse M; Campochiaro Peter A
Dynamic and quantitative analysis of choroidal neovascularization by fluorescein angiography.
Investigative ophthalmology & visual science 2006;47(12):5460-8.
-
2006: Nguyen Quan Dong; Shah Syed Mahmood; Hafiz Gulnar; Quinlan Edward; Sung Jennifer; Chu Karen; Cedarbaum Jesse M; Campochiaro Peter A;
A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
Ophthalmology 2006;113(9):1522.e1-1522.e14.
-
2005: Sahenk Z; Nagaraja H N; McCracken B S; King W M; Freimer M L; Cedarbaum J M; Mendell J R
NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.
Neurology 2005;65(5):681-9.
-
2004: Cedarbaum J
ALS endpoints. Survival.
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2004;5 Suppl 1():79-83.
-
2003: Parkman Henry P; Rao Satish S C; Reynolds James C; Schiller Lawrence R; Wald Arnold; Miner Philip B; Lembo Anthony J; Gordon James M; Drossman Douglas A; Waltzman Lynn; Stambler Nancy; Cedarbaum Jesse M;
Neurotrophin-3 improves functional constipation.
The American journal of gastroenterology 2003;98(6):1338-47.
-
2001: Cedarbaum J M; Stambler N
Disease status and use of ventilatory support by ALS patients. BDNF Study Group.
Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2001;2(1):19-22.
-
2000: Coulie B; Szarka L A; Camilleri M; Burton D D; McKinzie S; Stambler N; Cedarbaum J M
Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans.
Gastroenterology 2000;119(1):41-50.
-
1999: Kasarskis E J; Scarlata D; Hill R; Fuller C; Stambler N; Cedarbaum J M
A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials.
Journal of the neurological sciences 1999;169(1-2):118-25.
-
1999: Cedarbaum J M; Stambler N; Malta E; Fuller C; Hilt D; Thurmond B; Nakanishi A
The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).
Journal of the neurological sciences 1999;169(1-2):13-21.
-
1998: Cliffer K D; Siuciak J A; Carson S R; Radley H E; Park J S; Lewis D R; Zlotchenko E; Nguyen T; Garcia K; Tonra J R; Stambler N; Cedarbaum J M; Bodine S C; Lindsay R M; DiStefano P S
Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat.
Annals of neurology 1998;43(1):46-55.
-
1998: Stambler N; Charatan M; Cedarbaum J M
Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group.
Neurology 1998;50(1):66-72.
-
1997: Cedarbaum J M; Stambler N
Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials.
Journal of the neurological sciences 1997;152 Suppl 1():S1-9.
-
1997: Cedarbaum J M
Stability of levodopa/carbidopa solutions.
Movement disorders : official journal of the Movement Disorder Society 1997;12(4):625.
-
1997: Anand P; Terenghi G; Birch R; Wellmer A; Cedarbaum J M; Lindsay R M; Williams-Chestnut R E; Sinicropi D V
Endogenous NGF and CNTF levels in human peripheral nerve injury.
Neuroreport 1997;8(8):1935-8.
-
1997: Penn R D; Kroin J S; York M M; Cedarbaum J M
Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
Neurosurgery 1997;40(1):94-9; discussion 99-100.
-
1996: Cedarbaum J M; DeStefano P S; Lakings D B; Lindsay R M
Re: Pharmacokinetics and pharmacodynamics of rHCNTF in rodents.
Annals of neurology 1996;39(4):552-4.
-
1995: Ikeda K; Klinkosz B; Greene T; Cedarbaum J M; Wong V; Lindsay R M; Mitsumoto H
Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease.
Annals of neurology 1995;37(4):505-11.
-
1995: Anand P; Parrett A; Martin J; Zeman S; Foley P; Swash M; Leigh P N; Cedarbaum J M; Lindsay R M; Williams-Chestnut R E
Regional changes of ciliary neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral cortex from patients with motor disease.
Nature medicine 1995;1(2):168-72.
-
1995: Ikeda K; Wong V; Holmlund T H; Greene T; Cedarbaum J M; Lindsay R M; Mitsumoto H
Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease.
Annals of neurology 1995;37(1):47-54.
-
1994: Mitsumoto H; Ikeda K; Klinkosz B; Cedarbaum J M; Wong V; Lindsay R M
Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF.
Science (New York, N.Y.) 1994;265(5175):1107-10.
-
1994: Mitsumoto H; Ikeda K; Holmlund T; Greene T; Cedarbaum J M; Wong V; Lindsay R M
The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease.
Annals of neurology 1994;36(2):142-8.
-
1993: Lindsay R M; Altar C A; Cedarbaum J M; Hyman C; Wiegand S J
The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Experimental neurology 1993;124(1):103-18.
-
1993: Woodward W R; Olanow C W; Beckner R M; Hauser R A; Gauger L L; Cedarbaum J M; Nutt J G
The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses.
Neurology 1993;43(9):1704-8.
-
1993: Guttman M; Léger G; Reches A; Evans A; Kuwabara H; Cedarbaum J M; Gjedde A
Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa.
Movement disorders : official journal of the Movement Disorder Society 1993;8(3):298-304.
-
1992: Aisen M L; Dietz M A; Rossi P; Cedarbaum J M; Kutt H
Clinical and pharmacokinetic aspects of high dose oral baclofen therapy.
The Journal of the American Paraplegia Society 1992;15(4):211-6.
-
1992: Guttman M; Léger G; Cedarbaum J M; Reches A; Woodward W; Evans A; Diksic M; Gjedde A
3-O-methyldopa administration does not alter fluorodopa transport into the brain.
Annals of neurology 1992;31(6):638-43.
-
1991: Cedarbaum J M; Olanow C W
Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
Neurology 1991;41(10):1567-70.
-
1991: Cedarbaum J M; Leger G; Guttman M
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease.
Clinical neuropharmacology 1991;14(4):330-42.
-
1991: Koller W C; Block G A; Ahlskog J E; Ahrens S; Cedarbaum J M; Cyhan G; Goetz C G; LeWitt P A; Liss C; McLean L
Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
Clinical neuropharmacology 1991;14(4):322-9.
-
1991: Cedarbaum J M; Toy L H; Green-Parsons A
L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations.
Clinical neuropharmacology 1991;14(3):228-34.
-
1991: Cedarbaum J M; Gandy S E; McDowell F H
"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
Neurology 1991;41(5):622-9.
-
1991: Olanow C W; Gauger L L; Cedarbaum J M
Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
Annals of neurology 1991;29(5):556-9.
-
1990: Gandy S E; Grebb J A; Rosen N; Albert K A; Devinsky O; Blumberg H; Anderson N; Cedarbaum J M; Porter R J; Sedvall G
General assay for phosphoproteins in cerebrospinal fluid: a candidate marker for paraneoplastic cerebellar degeneration.
Annals of neurology 1990;28(6):829-33.
-
1990: Cedarbaum J M; Léger G; Reches A; Guttman M
Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
Clinical neuropharmacology 1990;13(6):544-52.
-
1990: Cedarbaum J M; Sheu K F; Harding B J; Blass J P; Javoy-Agid F; Agid Y
Deficiency of glutamate dehydrogenase in postmortem brain samples from parkinsonian putamen.
Annals of neurology 1990;28(1):111-2.
-
1990: Cedarbaum J M; Silvestri M; Kutt H
Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements.
Neurology 1990;40(6):995-7.
-
1990: Cedarbaum J M
Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Neurologic clinics 1990;8(1):31-49.
-
1990: Cedarbaum J M; Silvestri M; Clark M; Harts A; Kutt H
L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson's disease.
Clinical neuropharmacology 1990;13(1):29-35.
-
1990: Cedarbaum J M; Silvestri M; Clark M; Toy L; Harts A; Green-Parsons A; McDowell F H
Results of long-term treatment with controlled-release levodopa/carbidopa (Sinemet CR).
Journal of neural transmission. Parkinson's disease and dementia section 1990;2(3):205-13.
-
1990: Cedarbaum J M; Clark M; Toy L H; Green-Parsons A
Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
Movement disorders : official journal of the Movement Disorder Society 1990;5(4):298-303.
-
1989: Cedarbaum J M; Kutt H; McDowell F H
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Neurology 1989;39(11 Suppl 2):38-44; discussion 59.
-
1989: Cedarbaum J M
The promise and limitations of controlled-release oral levodopa administration.
Clinical neuropharmacology 1989;12(3):147-66.
-
1989: Cedarbaum J M; Hoey M; McDowell F H
A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance.
Journal of neurology, neurosurgery, and psychiatry 1989;52(2):207-12.
-
1988: Sheu K F; Blass J P; Cedarbaum J M; Kim Y T; Harding B J; DeCicco J
Mitochondrial enzymes in hereditary ataxias.
Metabolic brain disease 1988;3(2):151-60.
-
1988: Cedarbaum J M; Hoey M; Kutt H; McDowell F H
Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Clinical neuropharmacology 1988;11(2):168-73.
-
1988: Cedarbaum J M; Kutt H; McDowell F H
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Neurology 1988;38(4):533-6.
-
1988: Blass J P; Sheu R K; Cedarbaum J M
Energy metabolism in disorders of the nervous system.
Revue neurologique 1988;144(10):543-63.
-
1987: Porter L L; Cedarbaum J M; O'Leary D D; Stanfield B B; Asanuma H
The physiological identification of pyramidal tract neurons within transplants in the rostral cortex taken from the occipital cortex during development.
Brain research 1987;436(1):136-42.
-
1987: Cedarbaum J M; Breck L; Kutt H; McDowell F H
Controlled-release levodopa/carbidopa. II. Sinemet CR4 treatment of response fluctuations in Parkinson's disease.
Neurology 1987;37(10):1607-12.
-
1987: Cedarbaum J M
Clinical pharmacokinetics of anti-parkinsonian drugs.
Clinical pharmacokinetics 1987;13(3):141-78.
-
1987: Cedarbaum J M; Williamson R; Kutt H
Simultaneous determination of levodopa, its metabolites and carbidopa in clinical samples.
Journal of chromatography 1987;415(2):393-9.
-
1987: Cedarbaum J M; Breck L; Kutt H; McDowell F H
Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Neurology 1987;37(2):233-41.
-
1987: Cedarbaum J M; McDowell F H
Sixteen-year follow-up of 100 patients begun on levodopa in 1968: emerging problems.
Advances in neurology 1987;45():469-72.
-
1986: Cedarbaum J M; Blass J P
Mitochondrial dysfunction and spinocerebellar degenerations.
Neurochemical pathology 1986;4(1):43-63.
-
1986: Cedarbaum J M; Kutt H; Dhar A K; Watkins S; McDowell F H
Effect of supplemental carbidopa on bioavailability of L-dopa.
Clinical neuropharmacology 1986;9(2):153-9.
-
1978: Cedarbaum J M; Aghajanian G K
Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism.
Life sciences 1978;23(13):1383-92.
-
1978: Cedarbaum J M; Aghajanian G K
Afferent projections to the rat locus coeruleus as determined by a retrograde tracing technique.
The Journal of comparative neurology 1978;178(1):1-16.
-
1977: Aghajanian G K; Cedarbaum J M; Wang R Y
Evidence for norepinephrine-mediated collateral inhibition of locus coeruleus neurons.
Brain research 1977;136(3):570-7.
-
1977: Cedarbaum J M; Aghajanian G K
Catecholamine receptors on locus coeruleus neurons: pharmacological characterization.
European journal of pharmacology 1977;44(4):375-85.
-
1977: Davis M; Cedarbaum J M; Aghajanian G K; Gendelman D S
Effects of clonidine on habituation and sensitization of acoustic startle in normal, decerebrate and locus coeruleus lesioned rats.
Psychopharmacology 1977;51(3):243-53.
-
1976: Cedarbaum J M; Aghajanian G K
Noradrenergic neurons of the locus coeruleus: inhibition by epinephrine and activation by the alpha-antagonist piperoxane.
Brain research 1976;112(2):413-9.
Sign-in to see more
